Immune Design Obtains Vaccine Booster From IDRI

Xconomy Seattle — 

Immune Design, the Seattle-based vaccine development company, has obtained a worldwide exclusive license to develop a vaccine-boosting compound invented at the Infectious Disease Research Institute (IDRI). The technology, a glycopyranosyl lipid adjuvant, may be used to enhance the effectiveness of vaccines. The nonprofit IDRI will receive an upfront payment, milestone payments on success in testing, and royalties from sales if it ever turns into a product, as well as shares in Immune Design, a startup that raised $18 million in a Series A venture round in June.